Guardant Health, Inc. (GH): Price and Financial Metrics

Guardant Health, Inc. (GH): $54.89

5.30 (+10.69%)

POWR Rating

Component Grades













GH POWR Grades

  • Sentiment is the dimension where GH ranks best; there it ranks ahead of 42.05% of US stocks.
  • GH's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • GH's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).

GH Stock Summary

  • GH's went public 3.98 years ago, making it older than just 18.02% of listed US stocks we're tracking.
  • GH's price/sales ratio is 12.03; that's higher than the P/S ratio of 91.18% of US stocks.
  • The volatility of GUARDANT HEALTH INC's share price is greater than that of 79.18% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to GUARDANT HEALTH INC, a group of peers worth examining would be GBT, CERS, PLSE, IPWR, and CRMD.
  • GH's SEC filings can be seen here. And to visit GUARDANT HEALTH INC's official web site, go to

GH Valuation Summary

  • In comparison to the median Healthcare stock, GH's EV/EBIT ratio is 240% lower, now standing at -11.2.
  • Over the past 48 months, GH's price/sales ratio has gone down 41.7.

Below are key valuation metrics over time for GH.

Stock Date P/S P/B P/E EV/EBIT
GH 2022-09-23 12.3 15.7 -9.1 -11.2
GH 2022-09-22 12.5 16.0 -9.2 -11.4
GH 2022-09-21 13.5 17.2 -10.0 -12.1
GH 2022-09-20 13.9 17.8 -10.3 -12.5
GH 2022-09-19 13.8 17.6 -10.2 -12.3
GH 2022-09-16 14.0 18.0 -10.4 -12.5

GH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GH has a Quality Grade of C, ranking ahead of 48.47% of graded US stocks.
  • GH's asset turnover comes in at 0.158 -- ranking 71st of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows GH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.665 -0.174
2021-03-31 0.166 0.662 -0.187
2020-12-31 0.199 0.677 -0.197
2020-09-30 0.244 0.683 -0.205
2020-06-30 0.249 0.677 -0.147
2020-03-31 0.258 0.683 -0.108

GH Price Target

For more insight on analysts targets of GH, see our GH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.39 Average Broker Recommendation 1.27 (Strong Buy)

GH Stock Price Chart Interactive Chart >

Price chart for GH

GH Price/Volume Stats

Current price $54.89 52-week high $126.36
Prev. close $49.59 52-week low $27.65
Day low $50.18 Volume 904,700
Day high $55.15 Avg. volume 1,189,446
50-day MA $52.17 Dividend yield N/A
200-day MA $59.31 Market Cap 5.61B

Guardant Health, Inc. (GH) Company Bio

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.

GH Latest News Stream

Event/Time News Detail
Loading, please wait...

GH Latest Social Stream

Loading social stream, please wait...

View Full GH Social Stream

Latest GH News From Around the Web

Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.

Blood Tests for Cancer Look More Competitive. What It Means for Illumina’s Antitrust Fight.

The gene-sequencing company is fighting antitrust regulators on two continents as it seeks to hold on to Grail, which it bought last year.

Yahoo | September 20, 2022

Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

PALO ALTO, Calif., September 09, 2022--Guardant Health introduces GuardantINFINITY, a smart liquid biopsy providing multi-dimensional insights to advance cancer research & drug development.

Yahoo | September 9, 2022

“Defensive Mode”: Japanese Billionaire Masayoshi Son is Dumping These 8 Stocks

In this article, we discuss the 8 stocks that Japanese billionaire Masayoshi Son is dumping. If you want to skip our discussion on the recent losses incurred by Mr. Son, go to Japanese Billionaire Masayoshi Son is Dumping These 4 Stocks. Masayoshi Son’s SoftBank Group Corp. (OTC:SFTBY) reported its highest-ever quarterly loss of over $23 […]

Yahoo | September 7, 2022

Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients

PALO ALTO, Calif., September 06, 2022--Guardant Health will showcase data at ESMO 2022 demonstrating the utility of its portfolio of blood tests for advanced-stage cancer patients.

Yahoo | September 6, 2022

Why Guardant Health Crushed the Market Today

Guardant Health announced that it has increased its cooperation with that pharmaceutical company, the sprawling Merck & Co. (NYSE: MRK). The deal centers on the former company's GuardantINFORM diagnostics platform, which Merck will use to help develop the products in its precision oncology pipeline. Guardant data scientists will work closely with their Merck colleagues to disseminate the data supplied by the platform, the company said.

Yahoo | August 31, 2022

Read More 'GH' Stories Here

GH Price Returns

1-mo 9.45%
3-mo 36.07%
6-mo -24.85%
1-year -55.19%
3-year -12.30%
5-year N/A
YTD -45.12%
2021 -22.39%
2020 64.93%
2019 107.87%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5059 seconds.